离心式及膜式双重血浆分子吸附系统联合低剂量血浆置换治疗肝衰竭的对比分析

胡艳 ,  朱帮强 ,  王海婧 ,  杨鹏 ,  许伟 ,  卞茂红 ,  张骏飞 ,  达珍 ,  刁玉洁

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 859 -866.

PDF (1307KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 859 -866. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.07.007
论著

离心式及膜式双重血浆分子吸附系统联合低剂量血浆置换治疗肝衰竭的对比分析

作者信息 +

Comparative analysis of centrifugal and membrane double plasma molecular adsorption systems combined with low-dose plasma exchange in the treatment of liver failure

Author information +
文章历史 +
PDF (1337K)

摘要

目的 探究离心式及膜式双重血浆分子吸附系统(DPMAS)联合低剂量血浆置换在肝衰竭中的应用效果和安全性。方法 回顾性分析2024年4月至2025年6月本院收治的肝衰竭患者共60例,根据血浆分离方式不同,分为离心式DPMAS组(30例)和普通膜式DPMAS组(30例)。比较2组运行参数、实验室指标及不良反应等方面的区别。结果 在吸附及置换相同血浆量的条件下(P均>0.05),离心式组总循环血量、全血流速和治疗时间均低于膜式组[10 794(9 532,12 637)vs. 19 000(19 000,21 000)mL,60(60,65)vs. 125(120,130)mL/min,169(141,193)vs. 207(183,210)min,P均<0.001];离心式组中心静脉导管穿刺率更低[(24/30,80.00%)vs.(30/30,100.00%),P=0.024];离心式组使用枸橼酸钠溶液抗凝,需要补充更多钙剂[6(6,8)vs. 2(2,2)g,P<0.001]。离心式组治疗前后WBC、Hb、HCT和PLT均未见明显变化(P均>0.05);膜式组治疗前后WBC无统计学差异(P=0.199),但治疗后Hb、HCT和PLT值较治疗前均有明显下降[106.50(102.75,126.75)vs. 123.00(109.75,132.00)g/L,33.20(29.90,34.92)vs. 34.85(31.55,37.52)%,85.00(43.25,139.50)vs. 93.00(61.50,145.00)×109/L,P均<0.05]。离心式组治疗前后凝血功能指标均无统计学差异(P均>0.05);膜式组Fib在治疗后下降[1.50(1.20,1.60)vs. 1.60(1.25,1.80)g/L,P=0.033]。2组患者治疗后TBil、DBil均显著下降[离心式:194.70(107.50,276.00)vs. 239.15(173.00,304.17)μmol/L,101.00(64.00,182.30)vs. 157.00(101.00,195.00)μmol/L;膜式:211.50(118.00,240.00)vs. 263.50(204.75,314.00)μmol/L,188.00(122.75,232.25)vs. 219.00(178.50,267.25)μmol/L,P均<0.05]。离心式组患者导管相关并发症发生率较低[(2/30,6.67%)vs.(8/30,26.67%),P=0.038]。结论 离心式DPMAS组具有血流速度要求低、治疗耗时短、对血小板影响小、不良事件发生率低等优点,具有较好的应用前景。

Abstract

Objective To investigate the efficacy and safety of centrifugal and membrane double plasma molecular adsorption systems (DPMAS) combined with low-dose plasma exchange in the treatment of liver failure. Methods A retrospective analysis was performed on 60 patients with liver failure treated in our hospital from April 2024 to June 2025. Based on different plasma separation methods, they were divided into the centrifugal DPMAS group (n=30) and the conventional membrane DPMAS group (n=30). The operational parameters, laboratory indicators, and adverse reactions were compared between the two groups. Results Under the same plasma volume for adsorption and exchange (P>0.05), the centrifugal group showed lower total circulating blood volume, total blood flow rate, and treatment duration compared to the membrane group [10 794(9 532,12 637) vs 19 000(19 000,21 000)mL, 60(60,65) vs 125(120,130)mL/min, 169(141,193) vs 207(183,210) min, P < 0.001]. The centrifugal group also had a lower rate of central venous catheter use[(24/30,80.00%) vs (30/30,100.00%), P=0.024] and required more calcium supplementation due to sodium citrate anticoagulation [6(6,8) vs 2(2,2)g, P<0.001]. No significant changes were observed in WBC, Hb, HCT, and PLT levels before and after treatment with the centrifugal group (P>0.05). There was no statistically significant difference in WBC levels before and after membrane group treatment (P=0.199), but the values of Hb, HCT, and PLT showed significant decreases post-treatment compared to pre-treatment [106.50(102.75,126.75) vs 123.00(109.75,132.00) g/L, 33.20(29.90,34.92) vs 34.85(31.55,37.52)%, 85.00(43.25,139.50) vs 93.00(61.50,145.00)×109/L, P<0.05]. There was no significant difference in coagulation function indexes before and after treatment with centrifugal group (P>0.05). The membrane group showed reduction in fibrinogen (Fib) levels post-treatment [1.50(1.20,1.60) vs 1.60(1.25,1.80)g/L, P=0.033]. Both groups demonstrated significant decreases in total bilirubin (TBil) and direct bilirubin (DBil) levels after treatment (centrifugal group:194.70(107.50,276.00) vs 239.15(173.00,304.17)μmol/L, 101.00(64.00,182.30) vs 157.00(101.00,195.00) μmol/L; membrane group:211.50(118.00,240.00) vs 263.50(204.75,314.00) μmol/L, 188.00(122.75,232.25) vs 219.00(178.50,267.25) μmol/L, P<0.05]. The incidence of catheter-related complications was lower in the centrifugal group [(2/30,6.67%) vs (8/30,26.67%), P=0.038]. Conclusion The centrifugal DPMAS system demonstrates advantages such as lower blood flow velocity requirements, shorter treatment duration, minimal impact on platelets, and reduced adverse event rates, indicating promising clinical applications.

关键词

肝衰竭 / 双重血浆分子吸附系统 / 离心 / 膜 / 血浆置换

Key words

liver failure / double plasma molecular adsorption system / centrifugation / membrane / plasma exchange

引用本文

引用格式 ▾
胡艳,朱帮强,王海婧,杨鹏,许伟,卞茂红,张骏飞,达珍,刁玉洁. 离心式及膜式双重血浆分子吸附系统联合低剂量血浆置换治疗肝衰竭的对比分析[J]. 中国输血杂志, 2026, 39(7): 859-866 DOI:10.13303/j.cjbt.issn.1004-549x.2026.07.007

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

WAITZ G, ATIYE S, GAULY A, et al. Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia[J].Ther Apher Dial, 2022, 26(6):1281-1288.

[2]

MARLU R, NACIRI BENNANI H, SEYVE L, et al. Comparison of three modalities of plasmapheresis on coagulation: centrifugal, single-membrane filtration, and double-filtration plasmapheresis[J].J Clin Apher, 2021, 36(3):408-419.

[3]

YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J].J Clin Apher, 2019, 34(4):392-398.

[4]

中华医学会肝病学分会重型肝病与人工肝学组,中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南(2024年版)[J].临床肝胆病杂志, 2024, 40(12):2371-2387.

[5]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guideline for diagnosis and treatment of liver failure (2024 version)[J].J Clin Hepatol, 2024, 40(12):2371-2387.

[6]

中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会感染病学分会肝衰竭与人工肝专家委员会,国家感染性疾病临床医学研究中心,等. 人工肝血液净化系统治疗指南(2023年版)[J].中华临床感染病杂志, 2023, 16(6):401-411.

[7]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, et al. Guidelines on application of artificial liver blood purification system (version 2023)[J].Chin J Clin Infect Dis, 2023, 16(6):401-411.

[8]

TANDON R, FROGHI S. Artificial liver support systems[J].J Gastroenterol Hepatol, 2021, 36(5):1164-1179.

[9]

ZHU X F, LI J Q, LIU T T, et al. A single center retrospective study:comparison between centrifugal separation plasma exchange with ACD-A and membrane separation plasma exchange with heparin on acute liver failure and acute on chronic liver failure[J].J Clin Apher, 2024, 39(1):e22103.

[10]

XU W, ZHU S, YANG L, et al. Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure[J].J Med Virol, 2023, 95(3):e28650.

[11]

中国肝炎防治基金会双重血浆分子吸附系统临床应用及操作技术规范专家组. 双重血浆分子吸附系统的临床应用及操作技术规范[J].中华肝脏病杂志, 2024, 32(12):1073-1085.

[12]

Expert Group of Double Plasma Molecular Adsorption System for the Clinical Application and Operational Specifications in Chinese Foundation for Hepatitis Prevention and Control. Clinical application and technical operation specification of dual plasma molecular adsorption system[J].Chin J Hepatol, 2024, 32(12):1073-1085.

[13]

LAMBERT C, GERICKE M, SMITH R, et al. Plasma extraction rate and collection efficiency during therapeutic plasma exchange with Spectra Optia in comparison with Haemonetics MCS+[J].J Clin Apher, 2011, 26(1):17-22.

[14]

DONG J, HUANG L, LI C, et al. Clinical efficacy of centrifugal-membranous hybrid double filtration plasmapheresis and membranous double filtration plasmapheresis on severe lupus nephritis[J].Lupus, 2023, 32(9):1066-1074.

[15]

李园,卢晓莲,许万藏,等. 双重血浆分子吸附系统的人工肝治疗:离心式和膜式血浆分离的有效性和安全性比较[J].中华肝脏病杂志, 2024, 32(12):1109-1115.

[16]

LI Y, LU X L, XU W C, et al. Comparison of the effectiveness and safety profile of centrifugal and membrane plasma separation in artificial liver therapy with a dual plasma molecular adsorption system[J].Chin J Hepatol, 2024, 32(12):1109-1115.

[17]

周丽华,匡祖颖,叶锦龙,等. 离心式血浆分离模式下的蛋白A免疫吸附治疗视神经脊髓炎谱系疾病的疗效及安全性[J].中国神经免疫学和神经病学杂志, 2025, 32(4):291-295.

[18]

ZHOU L H, KUANG Z Y, YE J L, et al. Efficacy and safety of centrifugal plasma separation combined with protein A immunoadsorption in neuromyelitis optica spectrum disorder:a clinical analysis[J].Chin J Neuroimmunol Neurol, 2025, 32(4):291-295.

[19]

NIU L, ZHOU J, ZHAO N, et al. Safety and efficacy of DPMAS in patients with acute-on-chronic liver failure based on different platelet count levels[J].J Clin Apher, 2025, 40(1):e70006.

[20]

MALICEV E, KOZAK M, ROZMAN P. Evaluation of a flow cytometric assay for the confirmation of heparin-induced thrombocytopenia[J].Int J Lab Hematol, 2016, 38(3):240-245.

[21]

DENG Y, XING J, TAN Z, et al. Clinical application of 4% sodium citrate and heparin in the locking of central venous catheters (excluding dialysis catheters) in intensive care unit patients:a pragmatic randomized controlled trial[J].PLoS One, 2023, 18(7):e0288117.

[22]

KEKLIK M, CELIK S, YILDIZHAN E. Comparison of centrifugal and membrane filtration modalities on therapeutic plasma exchange[J].J Clin Apher, 2022, 37(3):217-222.

[23]

OHKUBO A, OKADO T, MIYAMOTO S, et al. Fibrinogen reduction during selective plasma exchange due to membrane fouling[J].Ther Apher Dial, 2017, 21(3):232-237.

[24]

XIANG Y, LI R, CAI J, et al. Three artificial liver models of treatment of acute-on-chronic liver failure[J].Ther Clin Risk Manag, 2024, 20:731-740.

[25]

BOISSON C, NADER E, RENOUX C, et al. Shear-stress-gradient and oxygen-gradient ektacytometry in sickle cell patients at steady state and during vaso-occlusive crises[J].Cells, 2022, 11(3):585.

[26]

潘寒寒,孟园园,王亚红,等. 急性肝衰竭人工肝系统支持发生血浆分离器破膜危险因素分析[J].医学理论与实践, 2023, 36(10):1739-1741.

[27]

PAN H H, MENG Y Y, WANG Y H, et al. Analysis of risk factors for plasma separator rupture in artificial liver system support for acute liver failure[J].J Med Theory Pract, 2023, 36(10):1739-1741.

[28]

BAI M, YU Y, ZHAO L, et al. Regional citrate anticoagulation versus no anticoagulation for CKRT in patients with liver failure with increased bleeding risk[J].Clin J Am Soc Nephrol, 2024, 19(2):151-160.

[29]

DHIR H, KUMAR D, SHAH D, et al. Efficacy of oral vs. intravenous calcium supplementation for continuation therapy in hypocalcemic seizures: a randomized, controlled trial[J].Indian J Pediatr, 2023, 90(5):433-437.

基金资助

西藏自治区自然科学基金组团式援藏医学项目(XZZR202402010(W))

AI Summary AI Mindmap
PDF (1307KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉